2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of 1st Line Options for PD-L1 +/- Cancers With(out) BRCA 1/2. Exploring the Optimal ET Agent to Combine With Palbociclib in the First-line Endocrine-sensitive Disease

703 views
July 13, 2020
Comments 0
Login to view comments. Click here to Login